Stanford University School of Medicine

Surgical Theater Announces First Augmented Reality Spine Surgery at Stanford Medicine Successfully Executed with SyncAR® Spine

Retrieved on: 
Thursday, October 19, 2023
Neoplasm, 3D, Surgeon, Extended reality, Extension, Microsoft, Health, Spine, Medicine, Partnership, XR, Surgery, Microsoft HoloLens, Patient, SAN, Stanford University School of Medicine, Dentistry, Neurosurgery

SAN FRANCISCO, Oct. 19, 2023 /PRNewswire/ -- Surgical Theater is proud to announce a groundbreaking achievement with Stanford Medicine performing the first spine surgery utilizing its augmented reality technology.

Key Points: 
  • SAN FRANCISCO, Oct. 19, 2023 /PRNewswire/ -- Surgical Theater is proud to announce a groundbreaking achievement with Stanford Medicine performing the first spine surgery utilizing its augmented reality technology.
  • The augmented reality spine surgery was done using Surgical Theater SyncAR® Spine, which integrates the Microsoft HoloLens headsets.
  • Stanford Medicine and Surgical Theater, longstanding partners in the quest for innovation in XR (Extended Reality) surgical care, are once again at the forefront of medical advancement with this cutting-edge technology being used in the operating room.
  • Dr. Gary Steinberg, Professor of Neurosurgery, and a Neurosurgeon at Stanford Medicine, emphasizes the transformative impact of Surgical Theater's technology on medicine and patient care.

Revvity, Inc. and Element Biosciences, Inc. Pioneer Next-Generation Sequencing Kits Market with Innovative Genomic Analysis Solutions

Retrieved on: 
Wednesday, October 18, 2023
WHO, Laboratory, Data analysis, DSM-IV codes, Sickle cell disease, Next, Genetics, Conditional sentence, Organization, Research, Illumina, Inc., Genomics, Growth, NGS, World Health Organization, Partnership, Cystic fibrosis, Workflow, Infection, Agilent Technologies, Cancer, Collection, Patient, Death, DNA, Stanford University School of Medicine, Retail, Vaccine, Illumina

The "Next Generation Sequencing Kits Market " report added to ResearchAndMarkets.com's offering provides valuable insights into this groundbreaking advancement.

Key Points: 
  • The "Next Generation Sequencing Kits Market " report added to ResearchAndMarkets.com's offering provides valuable insights into this groundbreaking advancement.
  • Genomic data, generated by next-generation sequencing (NGS), has become an essential driving force behind scientific innovation and research.
  • The global Next Generation Sequencing Kits market is segmented based on workflow, sequencing type, usage area, application, and end users.
  • Several prominent players are at the forefront of driving innovation in the Global Next Generation Sequencing Kits Market.

Beyond Cancer™ Publishes Pre-Clinical Data in Cells Demonstrating that the Combination of Ultra-High Concentration Nitric Oxide (UNO) and Anti-mPD-1 Therapy Improves Tumor Regression Rates and Survival in Mice

Retrieved on: 
Tuesday, October 17, 2023
Immunosuppression, Survival, Div, Stanford University School of Medicine, MD, Manuscript, PD-L1, Surgical oncology, UNO, 4T1, Administration, Immunotherapy, Associate, Science, PD-1, Pharmaceutical industry, Vaccine, M1, Surgery, Cell

GARDEN CITY, N.Y. and HAMILTON, Bermuda, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, announced today the publication of pre-clinical data demonstrating that its proprietary technology reduces immunosuppression and creates a favorable microenvironment that can contribute to immune potentiation.

Key Points: 
  • The data were published in an article entitled, “Intratumoral Administration of High-Concentration Nitric Oxide and Anti-mPD-1 Treatment Improves Tumor Regression Rates and Survival in CT26 Tumor-Bearing Mice,” in the peer-reviewed journal Cells.
  • The article is available on the Cells website.
  • “The combination of UNO and anti-mPD-1 resulted in a potent, synergistic immune response,” stated Dr. Hila Confino, Head of In Vivo Studies.
  • “I am excited for the presentation of our initial clinical data at SITC.”

CARGO Therapeutics Announces Appointment of Ginna Laport, MD, as Chief Medical Officer

Retrieved on: 
Tuesday, October 17, 2023
University, Stanford Cancer Institute, Antibody, Monoclonal antibody, Division, Drug, Research, Trial of the century, Stanford University School of Medicine, MD, Mosunetuzumab, BLA, IND, Health, Biotechnology, Medicine, Disease, Cancer, Patient, BA, Therapy, B-cell lymphoma, CAR, NME, CD22, Publication, SAN, CD19, BMT, Acceleration, Baylor University, B Division (New York City Subway), NIH, Pharmaceutical industry, Nursing, Stanford University, Blood

SAN MATEO, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CARGO), a clinical-stage biotechnology company uniquely positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced the appointment of Ginna Laport, MD, as Chief Medical Officer. Dr. Laport is a seasoned biotechnology executive and senior clinical leader. She will serve on the Company’s executive team and will be responsible for providing leadership and direction to guide CARGO’s clinical development strategy and execution, including the advancement of CARGO’s lead candidate, CRG-022, as well as its pipeline of next-generation CAR T-cell therapies for cancer patients. CRG-022 is an autologous CD22 chimeric antigen receptor (CAR) T-cell therapy candidate, currently in a potentially pivotal Phase 2 clinical trial in patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy.

Key Points: 
  • SAN MATEO, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CARGO), a clinical-stage biotechnology company uniquely positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced the appointment of Ginna Laport, MD, as Chief Medical Officer.
  • “We are thrilled to announce the addition of Ginna to our team as Chief Medical Officer.
  • With her extensive leadership background in clinical drug development, particularly in hematology/oncology, she brings invaluable expertise to our organization,” said Gina Chapman, CARGO’s President and Chief Executive Officer.
  • Previously, Dr. Laport was Chief Medical Officer at Tempest Therapeutics, where she directed the clinical development of small molecules that combine both tumor-targeted and immune-mediated mechanisms, including several IND submissions.

Coave Therapeutics appoints Leading World Experts to newly formed Scientific Advisory Board dedicated to its Genetic Medicine Delivery Platform

Retrieved on: 
Thursday, October 12, 2023
University of Pennsylvania, Knowledge, Doctor of Philosophy, Neuroscience, University of Massachusetts Chan Medical School, Education minister, CSO, Pediatrics, Stanford University School of Medicine, LDRI, Translational research, MD, Gene, United States Air Force Scientific Advisory Board, University, Duke University School of Medicine, Translation, Gene therapy, Université catholique de Louvain, Laboratory, AAV, Growth, Genetics, DSM-IV codes, DVM, LFCS, SAB, Patient, Vaccine, Management

Their collective expertise will also contribute to enhancing the ALIGATER™ platform and expanding its potential across viral (adeno-associated virus; AAV) and non-viral vector-based therapeutics, unlocking the potential to develop novel genetic medicines targeting serious diseases.

Key Points: 
  • Their collective expertise will also contribute to enhancing the ALIGATER™ platform and expanding its potential across viral (adeno-associated virus; AAV) and non-viral vector-based therapeutics, unlocking the potential to develop novel genetic medicines targeting serious diseases.
  • Lolita Petit, CSO of Coave Therapeutics commented, “We are absolutely thrilled to welcome our exceptional Scientific Advisory Board to the Coave team.
  • Each of these distinguished members has made profound contributions to the fields of genetic medicine, gene therapy, and neurosciences, bringing a unique depth of knowledge and experience to Coave.
  • We eagerly anticipate the opportunity to leverage their unique scientific insights to continue to advance our pipeline and ALIGATER platform.

Vivos Therapeutics to Begin Clinical Trial at Stanford Medicine

Retrieved on: 
Wednesday, October 11, 2023
Stanford University, Continuous positive airway pressure, DNA, AHI, Stanford University School of Medicine, Disease, FDA, Mouth, Therapy, CPAP, Clinical trial, Snoring, OSA, Patient, Pharmaceutical industry, Medical device, Vivos

LITTLETON, Colo., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company") (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from mild-to-moderate obstructive sleep apnea (OSA) and snoring in adults, announced that its flagship daytime-nighttime appliance (DNA) will be tested in a clinical trial at Stanford Medicine.

Key Points: 
  • LITTLETON, Colo., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company") (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from mild-to-moderate obstructive sleep apnea (OSA) and snoring in adults, announced that its flagship daytime-nighttime appliance (DNA) will be tested in a clinical trial at Stanford Medicine.
  • “While Vivos believes in these results, it is important to apply the highest standards in medical research in the form of a prospective randomized controlled trial.
  • This will truly test Vivos’ treatment to the same standard as all other modalities.”
    “We are extremely excited to be starting this trial at Stanford Medicine, which has been in the works for some time” added R. Kirk Huntsman, Chairman and CEO of Vivos.
  • “I am confident that our technology will bear the scrutiny of a well-designed, prospective clinical trial.

Jasper Therapeutics to Host Key Opinion Leader Webinar on the Potential of Briquilimab for Chronic Urticaria on October 11, 2023

Retrieved on: 
Monday, October 9, 2023
CSU, Basophil, Antibody, Biology, Inflammation, Apoptosis, Risk, Rockefeller, KOL, Stanford University School of Medicine, Survival, FCR, Microbiology, B cell, Transplant, Patient, Stem cell factor, Infection, Therapy, Stanford Institutes of Medicine Summer Research Program, CD117, Fraunhofer Society, Berlin, Immunology, Immunity, S-1 Executive Committee, Hives, Syndrome, Pharmacology, SCF, Rockefeller University, FC, Executive Committee, Translational medicine, Vaccine, Pathology, Dermatology, Allergy, Jasper

Jasper’s leadership team will also provide an overview of upcoming clinical studies which will evaluate briquilimab’s potential as a therapeutic for both CSU patients and CIndU patients.

Key Points: 
  • Jasper’s leadership team will also provide an overview of upcoming clinical studies which will evaluate briquilimab’s potential as a therapeutic for both CSU patients and CIndU patients.
  • Briquilimab is an unconjugated aglycosylated anti-c-Kit antibody that blocks the interaction of the c-Kit receptor from its ligand, stem cell factor (SCF).
  • This mechanism of action disrupts the critical survival signal, leading to mast cell apoptosis thereby removing the underlying source of the inflammatory response in chronic urticaria.
  • He is also a member of the Executive Committee of the Stanford Institute for Immunity, Transplantation and Infection.

Novocure and Stanford School of Medicine to Establish Tumor Treating Fields Research Program

Retrieved on: 
Thursday, October 12, 2023
Research, Medical Devices, Clinical Trials, Radiology, University, Health, Science, Education, Oncology, Other Science, Stanford University, GBM, Ependymoma, Bevacizumab, Survival, Stanford University School of Medicine, Medicine, Cancer, Patient, Temozolomide, Stanford School, TRIDENT, Meningioma, Pharmaceutical industry, Vaccine, Medulloblastoma

Novocure (NASDAQ: NVCR) today announced it has entered into an agreement with Stanford University to establish the Stanford School of Medicine Tumor Treating Fields (TTFields) Research Program.

Key Points: 
  • Novocure (NASDAQ: NVCR) today announced it has entered into an agreement with Stanford University to establish the Stanford School of Medicine Tumor Treating Fields (TTFields) Research Program.
  • The program is intended to support both preclinical studies and clinical trials with TTFields, electric fields that exert physical forces to kill cancer cells via a variety of mechanisms.
  • “We look forward to collaborating with Stanford Medicine to establish a research framework for preclinical and clinical development of TTFields,” said Moshe Giladi, Ph.D., Novocure’s Chief Science Officer.
  • At present, Stanford Medicine is a site for four clinical studies of TTFields therapy.

 GE HealthCare’s growing list of medical institutions conducting human subject research studies with its novel photon counting CTi technology further expands with the addition of Stanford Medicine

Retrieved on: 
Monday, October 9, 2023
Technology, Semiconductor, Hospitals, Other Health, Biotechnology, Radiology, University, Pharmaceutical, Health, Education, Photon, Silicon, MBA, Doctor of Philosophy, Research, MD, Institutional review board, Cardiology, Neurology, Absorption, Stanford University School of Medicine, Electrical engineering, Molecular imaging, General Electric, CE, Stanford Research Park, Assistant professor, GE, CT scan, Sale, GE HealthCare, Patient, University of Texas Health Science Center Department of Radiology, Medical imaging, Pharmaceutical industry

Altogether, it has the promise to be a substantial step forward for CT imaging that can potentially benefit millions of patients worldwide.

Key Points: 
  • Altogether, it has the promise to be a substantial step forward for CT imaging that can potentially benefit millions of patients worldwide.
  • Photon counting technology marks what is probably the most significant technological advancement in CT in more than a decade, and perhaps longer.”
    Stanford Medicine researchers will facilitate human subject research and produce technical feedback to test and help advance GE HealthCare’s photon counting CT technology with Deep Silicon.
  • From the first x-ray machines to the first silicon-based photon counting prototype, GE HealthCare is committed to pioneering next generation imaging technology.
  • GEiv researchers began studying photon counting CT in 1993 and developed the world’s first photon counting CT prototype using cadmium-based detectors in 2006.

Apollo.io Announces Olympus 2023, the Premiere Go-To-Market Sales Event

Retrieved on: 
Wednesday, October 11, 2023
Olympus, Stanford University School of Medicine, Ophthalmology, SDR, Science and technology in Asia, AI, Future, Fireside chats, Psychiatry, Blackwell, Growth, Marketing, White-Smith Music Publishing Co. v. Apollo Co., Neuroscience, SAN, Science, ChromeOS, Stanford School, Apollo, Y Combinator, 2023, GTM, Fine chemical, Nightclub, Sales, Management, Woman, Twitch

SAN FRANCISCO, Oct. 11, 2023 /PRNewswire/ -- Today Apollo.io, the leading go-to-market (GTM) solution for sales and marketing teams, announced Olympus 2023, the company's first-ever virtual event featuring keynote presentations and guest speakers who will explore the future of sales. Olympus is free and open to all attendees across sales, revenue operations, and marketing who want to learn how to build or enhance their go-to-market strategy, predictably forecast their pipeline amid economic uncertainty, develop stronger customer relationships, and bolster sales team's performance. This half day multi-session event, with the theme "Sell like a god", will be held on Wednesday, November 8th from 9:00am to 12:30pm Pacific (12:00pm to 3:30pm Eastern).

Key Points: 
  • Olympus is free and open to all attendees across sales, revenue operations, and marketing who want to learn how to build or enhance their go-to-market strategy, predictably forecast their pipeline amid economic uncertainty, develop stronger customer relationships, and bolster sales team's performance.
  • This half day multi-session event, with the theme "Sell like a god", will be held on Wednesday, November 8th from 9:00am to 12:30pm Pacific (12:00pm to 3:30pm Eastern).
  • "Olympus 2023 is not just another sales event.
  • Sessions that have presentations that are webcast will be broadcast live, and the replay will be available for a limited time post event.